Jubilant DraxImage is dedicated to providing radiopharmaceuticals for the diagnosis and treatment of a variety of diseases. We invite you to learn more about these areas and how our products are used by healthcare professionals to care for their patients.
About 1.1% of the population will be diagnosed with thyroid cancer in their lifetime.1 Incidence of thyroid cancer has been increasing faster than any other cancer in the US, tripling in the past 3 decades.2 This rise in incidence is in large part due to enhanced diagnostic techniques that detect small thyroid nodules that may have been missed otherwise.2
As with other thyroid diseases, thyroid cancer is 3 times more prevalent in women than men.2 Women are also more likely to be younger when they develop thyroid cancer, as risk peaks for women in their 40s or 50s, whereas men are usually diagnosed in their 60s or 70s.3
The most common types of thyroid cancers—papillary and follicular cancers—develop in the cells that produce the thyroid hormone and resemble healthy tissue. They are sometimes referred to together as differentiated thyroid cancer (DTC).
Other classifications of thyroid cancer:
Radioactive iodine (RAI) is a therapy used in the treatment of some thyroid cancers, specifically papillary and follicular thyroid cancer. Other types of thyroid cancers are not susceptible to radioactive iodine intervention.
Physicians may use one or more procedures to diagnose thyroid cancer, such as a physical exam, biopsy, blood tests, or imaging tests. A common nuclear imaging test called a radioiodine scan may be used to detect thyroid cancer or to show if the cancer has spread in patients already diagnosed. For this test, a patient is given a small amount of radioactive iodine that is absorbed by thyroid cells, which may be seen using a special camera hours later.
Most people treated for thyroid cancer have most or all the thyroid surgically removed.4; After surgery, patients will need hormone therapy to replace the hormones once produced by the thyroid gland.
Radioactive iodine—also known as iodine-131—may also be given following surgery to destroy remaining thyroid cells and thyroid cancer that may have spread to other areas of the body. This is effective because thyroid cells naturally and selectively absorb iodine, a mineral found in foods such as iodized salt, dairy product, eggs, and some seafood. When radioactive iodine is given to a patient it is absorbed by thyroid cells—including cancer cells—which it then destroys.
Despite treatment, thyroid cancer can return, even if the thyroid has been removed.4 Recurrence most often occurs in the first 5 years after surgery, but it can come back decades later.4 This may be a result of thyroid cancer cells spreading beyond the thyroid bed area in the neck prior to surgery.4 Post-operative treatment with radioactive iodine has been demonstrated to reduce the risk of recurrence in DTC patients.5
Jubilant DraxImage is committed to providing pharmaceuticalgrade radioactive iodine to enable physicians to accurately diagnose and treat thyroid cancer and help patients achieve and maintain remission.
The information provided above is not intended as medical advice. Patients must make sure that they have all the relevant information about their specific condition and discuss with their doctor to help make informed decisions about their therapy options.